Andhra Sugars FY26: The Chemistry of Quiet Repair

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Andhra Sugars closed FY26 with ₹83 Cr net profit on ₹2,466 Cr revenue — the same top line as FY22, a four-year flat spell broken only by FY23’s ₹2,368 Cr bump.

The margin story is muddled. Operating profit sank from ₹203 Cr (8.2% margin) in FY25 to ₹203 Cr again in FY26 — but from a ₹2,466 Cr base, that’s only 8.2% OPM, not enough to celebrate. Yet cash generation surprised: free cash flow hit ₹226 Cr in FY26, four times the ₹8 Cr trickle of FY25. That’s not recovery; that’s the company wringing cash from a shrinking asset base as it shuts sugar units.

The balance sheet carries zero net debt — a relief. The real tension: is ₹83 Cr a floor for a stabilizing chemicals business, or a pause before deeper pain?

What to watch: The caustic soda realisations that cratered the profit. ISRO offtake climbed to ₹68 Cr in FY26 from ₹35 Cr in FY25 — sharp acceleration. If that holds, the margin desert may have an oasis.

2. Introduction

Andhra Sugars is a 77-year-old diversified chemicals-and-sugar hybrid owned 50.5% by a tight family of promoters. The company spans caustic soda, industrial alcohol, sulphuric acid, rocket propellants for ISRO, and—once—sugar. Three sugar mills. Four business segments. Two continents’ worth of ambition, one state’s worth of execution.

FY26 saw a quiet reckoning. The Tanuku sugar unit was formally shuttered. Bhimadole and Taduvai remain mothballed, their crushing capacity of 16,000 tonnes per day idle. The decision cost ₹440 Cr in voluntary retirement payouts, ₹330 Cr in asset impairment, and another ₹2,097 Cr in a power-purchase cost recovery demand from Telangana discoms. Stripped of exceptional items, net profit was ₹119 Cr — still a step up from FY25’s ₹27 Cr standalone profit, but the headline ₹83 Cr muddies the story.

The chemical plants at Saggonda rumbled on. FY25’s new sulphuric acid unit, financed entirely from internal funds, came live. A salicylic acid plant (aspirin feedstock) is exporting again. The company is debt-free as of June 2025. ICRA reaffirmed its A+ rating in September with a Stable outlook. All of this is a slow re-calibration from sugar to specialty chemicals and space-grade propellants.

3. Business Model: WTF Do They Even Do?

Start with what died. Sugar was 8% of FY24 revenue. It made a ₹185 Cr loss in FY26 consolidated (before exceptional items). The company has now decided to stop trying, closing Tanuku and suspending the other two mills indefinitely. This is not bankruptcy; this is a father telling a losing son he’s off the allowance.

What remains is a chemical complex at Saggonda that looks like a Lego set a chemist forgot to finish.

Chlor-alkali (37% of FY26 standalone revenue, ₹778 Cr): Caustic soda (600 TPD capacity), caustic potash, chlorine, hydrochloric acid. The segment’s PBIT margin fell to 4.6% in FY25 from 6.6% in FY24 due to global caustic price softness. In Q1 FY26, margins recovered sharply to 16.9%, a sign that realisations improved. The company has a strong position in southern India, where caustic demand-supply is less brutal than up north.

Industrial Chemicals (36% of consolidated revenue, ₹1,341 Cr): Sulphuric acid, chlorine, hydrochloric acid, industrial alcohol, liquid and solid rocket propellants. ISRO offtake is the story. Revenue from propellants jumped to ₹68 Cr in FY26 from ₹35 Cr in FY25. The company supplies liquid rocket propellants (LPSC to ISRO). If the Indian space programme stays funded and launch cadence accelerates, this becomes the engine.

Soap (11% of consolidated revenue, ₹609 Cr, via Jocil subsidiary): Oleochemical stearic acids, distilled fatty acids, refined glycerine, soap. FY24 saw a 26% revenue decline year-on-year. The segment’s competitive position is narrow.

Power Generation (2% of consolidated revenue, ₹50 Cr): A 16.6 MW wind farm at Tamil Nadu feeds power to the Tamil Nadu grid. The segment made a loss in FY26 as it did in FY25. This is a burden asset.

Sugar (1% of consolidated revenue, ₹113 Cr, effectively zero going forward): The three mills, now shuttered, each had different personalities. Tanuku, the oldest, is gone. Bhimadole and Taduvai await a signal to restart. Crushing volume in H1 FY25 was 164,000 MT, down from 313,000 MT in FY24. The company does not publish FY26 crushing data; silence speaks.

The real business is chemicals. The aspiration is propellants. The albatross is everything else.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Full Year FY26:

What the headline hides: FY26’s net profit sits on two stilts. The first is a ₹307 Cr true-up credit from the power regulator (FPPCA order reversal) — a windfall, not operating income. The second is the absence of the ₹2,097 Cr discom penalty in FY25’s operating baseline, which now appears in FY26 as an exceptional cost. Adjust both out, and the underlying operating profit is roughly ₹121 Cr — marginal recovery from FY25’s chaos.

The EBITDA leap (from ₹108 Cr to ₹287 Cr) is real. It reflects higher revenue and lower depreciation after asset write-downs. Operating margin improved modestly from 5.4% to 11.6%, but this is a sugar-coated baseline shift, not a business transformation. Cost of goods sold rose from ₹1,920 Cr (95% of revenue in FY25) to ₹2,264 Cr (92% of revenue in FY26). Efficiency narrowed, not widened.

The balance sheet is fortress-like. Cash and equivalents stand at ₹170 Cr. Borrowings are ₹0.56 Cr, a rounding error. Interest coverage is 59x. The company paid ₹109 Cr in dividends on a ₹83 Cr net profit — not sustainable without asset sales or equity issuance, but the pool of ₹500 Cr in current investments absorbs it for now.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

P/E (11.2x): The market assigns a below-peer multiple despite an annualised EPS of ₹6.14. The peer set (SRF, GHCL, Deepak Fertilisers, Tata Chemicals) trades at 20x on average. Andhra Sugars trades below its own 5-year average of 10.8x only if EPS stays near ₹7–8 Cr. The discount reflects two risks: (1) the volatility and commodity nature of caustic soda realisations, and (2) the company’s sub-peer ROCE and ROE, which hint at capital misallocation (the dead sugar units consumed years of capex).

EV/EBITDA (4.57x): This sits 37% below the peer median of 7.2x. For a company in a commodity chemical business with volatile margins, the lower multiple is rational. The 5-year average was 5.1x; the current level is inside that band, suggesting fair equilibrium pricing if EBITDA stabilises at ₹250–300 Cr.

P/B (0.67x): The market pays ₹0.67 for every rupee of book value, the second-lowest in the peer set. SRF trades at 5.79x, GHCL at 1.11x, Deepak Fertilisers at 2.87x. Low P/B flags investor skepticism on the return on capital. Book value is ₹123 per share; the stock is ₹82.81. The shortfall is a bet that the assets (particularly sugar mill land and equipment) will not earn their cost of capital.

ROE (6.1%) and ROCE (8.5%): Both are weak, below peer medians of 6.6% and 9.5% respectively. The 5-year ROE averaged 7.9%. Current ROE suggests equity is being deployed at below-cost returns. Part of that is balance-sheet drag from inactive assets. Once sugar units are formally written off and optimized, ROE should inch toward 8–10%.

The market appears to be pricing in a slow normalization: moderate EBITDA stability (₹250–300 Cr), modest ROE recovery (toward 8%), and no re-rating upside unless (a) propellant offtake from ISRO accelerates durably, or (b) caustic soda realisations durably improve.

6. What’s Cooking

Shutdown of sugar mills (Mar 2026): Tanuku unit is formally closed. Bhimadole and Taduvai suspended indefinitely. This cost ₹440 Cr in VRS payouts, ₹330 Cr in asset impairment. Upside: no more annual operating losses from crushed margins and idle capacity. Downside: land and mill equipment now sit on balance sheet at write-down value. Restart costs are undefined.

Discom penalty for power purchase cost recovery (FY22–23, ₹2,097 Cr, paid in Q4 FY26): Telangana discoms demanded recovery of “Fuel and Power Purchase Cost Adjustment” (FPPCA) for FY22–23. The company, which generated power at Taduvai, fought and lost. The payment dented cash in Q4. A prior FY24–25 true-up credit of ₹307 Cr partially offset it. Net impact: a ₹1,790 Cr cash drag, much of which flows through FY26 P&L as exceptional loss.

ISRO propellant offtake acceleration (₹68 Cr in FY26 vs ₹35 Cr in FY25): Liquid rocket propellants from the Saggonda plant are being consumed at twice the prior year’s rate. The company supplies LPSC-grade propellants. ISRO’s Chandrayaan and Aditya-L1 missions drive demand. If this trend sustains (₹100+ Cr annually by FY28), industrial chemicals becomes a compounding growth story, not a commodity treadmill.

Sodium hypochlorite capex on hold (₹18 Cr planned, J.N. Pharmacity, Visakhapatnam): The company had secured a 42.28-acre site at a pharma complex in Visakhapatnam to build a 100 TPD sodium hypochlorite plant. APIIC (Andhra Pradesh Industrial Infrastructure Corporation) cancelled the allocation, citing non-compliance. The company is contesting in court. Capex is suspended pending outcome. If the company wins, a new 100 TPD capacity (₹18 Cr, sourcing chlorine from Saggonda) would support margin recovery. If it loses, no capex drag, but no growth option.

Dividend payout at 60% (₹1.20 per share in FY26 special + normal): The company recommended a dividend of ₹1.20 per share (60% payout) on ₹2 face value. Record date was 19 September 2026. This implies shareholder distribution of ₹163 Cr, against a ₹83 Cr net profit. The company is mining its ₹500 Cr liquid investments to fund this. Unsustainable if earnings stagnate, but a signal of confidence that liquidity is durable.

ICRA credit rating reaffirmation (September 2025): ICRA reaffirmed A+ (Stable) on fund-based working capital and short-term facilities. The agency noted the company’s “diversified business profile, robust leverage and coverage metrics, and strong liquidity position.” Interest cover is 56.2x. The Stable outlook reflects confidence in capital structure durability, not business growth. Risk flagged: exposure to ECU (electrochemical unit, i.e., caustic soda) pricing volatility and global supply-demand dynamics.

Profitability moderation due to caustic soda realisations (FY25–26): Caustic soda realisations softened in H2 FY25 and H1 FY26, pressuring margins. Q1 FY26 saw a sharp recovery (PBIT margin 16.9% in chlor-alkali, vs 4.6% in FY25), a sign that realisations bounced. If global caustic prices stay firmer, Q2–Q4 FY26 could show margin recovery.

7. Balance Sheet: Sab Dikhega

Validation: Assets (₹2,174 Cr) = Equity (₹1,672 Cr) + Liabilities (₹502 Cr). Balance.

Three dark humours:

1. Asset write-downs are the story, not growth. Net block (property, plant, equipment) rose from ₹813 Cr in FY25 to ₹931 Cr in FY26, but this includes the new sulphuric acid plant capitalized at Saggonda. Simultaneously, the company took a ₹330 Cr impairment charge on the Bhimadole sugar unit. Walk the numbers: gross capex was ₹533 Cr (sulphuric acid plant, some salicylic acid, wind farm maintenance), but depreciation was ₹83 Cr and impairment hit ₹330 Cr. Net block growth is a mirage—replacement capex for an aging fleet, not expansion.

2. Investments are the crumb drawer. The company holds ₹529 Cr in investments (up from ₹322 Cr in FY25), mostly in liquid funds and FDs. This is the cash reserve funding the dividend. Once it dips below ₹300 Cr (at current payout rates, in ~2 years), the company will either cut dividends or tap earnings. The quality of balance sheet depends on this cash lasting until caustic margins recover durably.

3. CWIP (capital work in progress) is a question mark. CWIP stood at ₹42 Cr in FY26 (down from ₹57 Cr in FY25). The company has a salicylic acid plant being commissioned and the sodium hypochlorite project on hold. The decay of CWIP suggests the sodium hypochlorite capex is unlikely in the near term. The salicylic acid plant should complete soon; aspirin is still a global commodity, and the company is trying to re-enter Haleon’s supply chain after GSK’s M&A shuffle knocked it out.

One wisdom line: A balance sheet with nothing to hide—zero debt, liquid reserves, and a fair book value—but no credible path to earning its cost of equity until the chemical business does more than survive.

8. Cash Flow: Sab Number Game Hai

Tracing the money:

Operating cash rose from ₹128 Cr (FY25) to ₹278 Cr (FY26). The ₹150 Cr jump came from two sources: (1) higher net profit before the discom penalty (₹119 Cr vs ₹28 Cr), and (2) a working capital release of ₹11.7 Cr as inventory shrank dramatically (from ₹315 Cr to ₹199 Cr), a direct result of the sugar mills shutting down. Receivables also improved (down from ₹228 Cr to ₹130 Cr), likely because chemical sales are more disciplined than sugar sales ever were. The quality of cash from operations is decent; it reflects organic inflows, not balance-sheet manipulation.

Investing cash outflow doubled to -₹246 Cr (from -₹93 Cr in FY25). The sulphuric acid plant and salicylic acid capex absorbed ₹533 Cr in purchase of fixed assets. Offsetting this, the company sold some current investments and received ₹318 Cr from maturity of bonds/FDs, a net investing outflow of ₹246 Cr. In other words: the company is trading liquid investments for fixed assets, a rational capital redeployment.

Free cash flow (operating – investing) surged to ₹32 Cr in FY25 and ₹226 Cr in FY26. This is real cash generation from the business, after capex. The FY26 spike is unsustainable if operating cash normalizes after the working-capital release wears off, but it shows the core business can fund dividends and debt reduction without tapping the investment reserve.

Financing cash was flat (-₹27 Cr in FY26, -₹34 Cr in FY25). Debt repayment was ₹1.3 Cr (minimal), and dividends paid were ₹109 Cr. The company funded the gap from operations and its investment portfolio. Lease payments were ₹0.02 Cr (negligible). This is a company in quiet capital optimization mode.

One wisdom line: Free cash of ₹226 Cr in a year of inventory clearance and asset write-downs is a mirage. When inventory rebounds (if sugar restarts) or the working capital wash reverses, FCF will normalize to ₹50–100 Cr. Plan accordingly.

9. Ratios: Sexy or Stressy?

ROE at 6.1% is below the cost of equity (assumed 9–10% for a small-cap chemical compounder). The equity is working part-time, a reflection of the dead sugar assets and a low-margin chemicals business. Once sugar mills are fully written off and ISRO propellant offtake scales, ROE should edge toward 8–9%. Still sub-optimal, but plausible.

ROCE at 8.5% suggests the capital employed is barely clearing the weighted cost of capital (assumed 8–9%). This is a business treading water, not swimming. The metric has trended up from 4% in FY25 only because the denominator (capital employed) fell faster than the numerator (profit) due to asset write-downs. Organic improvement is muted.

P/E at 11.2x is tight relative to history (5-year average 10.8x, but includes multi-year lows of 4x in FY24 and highs of 42x in FY25 when earnings crashed). Current P/E suggests the market is pricing in earnings stability at ₹6–7 per share annually. Upside comes if earnings re-rate to ₹10+ on ISRO-driven growth; downside if caustic realisations soften again and ISRO offtake plateaus.

PAT margin at 4.2% is below the 5-year average of 5.5%, but it’s honest. Chemicals are commodities; 4–5% net margins are the natural state before leverage or scale tilts the field. No magic here.

D/E at 0.00 is fortress health but also signals capital discipline. The company could lever ₹200–300 Cr without breaching A+ ratings, but it chooses not to. Implies either caution about near-term earnings stability or a belief that equity is the right fuel.

10. P&L Breakdown: Show Me the Money

Revenue trajectory: Flat for four years (FY22–26 averaged ₹2,070 Cr), then a sharp ₹2,466 Cr in FY26. The jump came from ISRO propellant acceleration (₹35→₹68 Cr), a 27% yoy sales growth in Q4, and chemicalsmix shift as sugar’s ₹1,000 Cr revenue was replaced by higher-margin industrial chemistry. The top line is stable, not growing.

EBITDA collapse and recovery: FY25 saw EBITDA crater to ₹108 Cr (a 43% YoY decline) due to caustic soda realisations falling off a cliff. FY26 recovered to ₹287 Cr as (a) realisations firmed, (b) revenue mix tilted toward propellants, and (c) the cost of goods as a % of sales shrank from 95% to 92%. This recovery is real, but fragile; it hinges on caustic prices not collapsing again.

PAT journey: Net profit fell from ₹76 Cr (FY24) to ₹26 Cr (FY25) to ₹83 Cr (FY26), but the FY26 figure is bloated by a ₹307 Cr regulatory true-up. Underlying PAT (backing out exceptional items and the FPPCA reversal) is ₹119 Cr—a credible base from which to forecast normalized earnings of ₹90–110 Cr.

The business is regaining footing after a brutal FY25. Whether it’s a platform for growth or a cycle top remains the open question.

11. Peer Comparison

Size gap: SRF is 6.4x larger. GHCL and Deepak Fertilisers are 1.2–4.7x larger. Andhra Sugars is a minnow competing in the chlor-alkali and specialty chemicals space. SRF, the titan, trades at 42.7x despite a 9% ROCE; it owns the market.

Profitability spread: SRF’s PBIT margin is 21.6% (specialty chemicals and polymers). GHCL’s is 22.5%. Andhra Sugars’ is 8.2% (Q4 FY26: 7.5%). The company is a commodity operator in a margin-starved segment. Tata Chemicals’ PBIT margin is 12.4% and its ROA is only 1.2%, suggesting legacy chlor-alkali capacity and asset write-downs akin to Andhra Sugars’ own.

Multiple gap (P/E): The peer set (excluding Tata Chemicals’ distressed 70x) trades at 20–42x. Andhra Sugars at 11.2x reflects (a) smaller size, (b) lower ROCE, (c) commodity exposure, and (d) the market’s caution about near-term earnings stability. The discount is justified on fundamentals, not emotion.

12. Miscellaneous: Shareholding & Promoters

Promoter base (50.5%): A tight family group. The top holders include Jansi Jayalakshmi Pendyala (3.6%), Sree Mullapudi Venkataramanamma Memorial (3.3%), Pendyala Sujatha (3.0%), P.S.R.V.K. Ranga Rao HUF (2.4%), and a host of family trusts and HUF entities. Promoter holding has drifted up from 47% in FY23 to 50.5% in FY26, a sign of minor family acquisitions on dips or estate consolidations. No pledges reported (1.02% per Screener data, minimal).

Bios & conduct: The Mullapudi and Pendyala families have controlled the company since 1947. No major governance scandals in the past decade. The current Chairman & Managing Director is P. Narendranath Chowdary. The board includes independent directors and meets quarterly. Related-party transactions are within normal bounds (inter-company loans, dividend payments, inter-company sales for ISRO business). The company has maintained dividend discipline even in down years, a signal of family confidence in the long game.

Micro-roast: The promoters kept the sugar business alive for four years (FY23–26) despite mounting losses, likely due to emotional attachment to a heritage business and sunk-cost bias. By the time they shut it down, the company had burned cash on idle mills and VRS payouts. A colder family would have exited in FY23. This is a family-controlled company’s classic weakness: legacy business sentiment over capital discipline. That said, the decision to shut down in FY26 shows learning.

FIIs and DIIs: Foreign institutional ownership is 2.5%, low for a BSE-listed company. No domestic institutional ownership (DIIs at 0%) despite strong credit ratings and a fortress balance sheet. This hints that the market sees the company as a small, regional chemical player, not a systemic opportunity. The absence of DIIs also means no meaningful analyst coverage outside Screener-style automated tracking.

13. Corporate Governance: Angels or Devils?

Auditors: Brahmayya & Co (Chartered Accountants, registration #000513S) audited both standalone and consolidated FY26 results. The audit opinion was unmodified, meaning no red flags from the statutory auditor. The firm has offices across India and a reputation for diligence.

Board & KMP: The company has a Chairman & Managing Director (P. Narendranath Chowdary, DIN 00015764), a Vice President Finance (listed as P.V.S. Viswan Adha Kumar on the May 30, 2026 board approval), and standard governance roles. Independent directors are listed, though names are not flagged in the documents. The audit committee reviewed results on May 29, 2026, before board approval on May 30, 2026.

Tax demands & regulatory actions: The company received a ₹2,097 Cr demand from Telangana discoms for FPPCA (Fuel and Power Purchase Cost Adjustment) recovery for FY22–23. The company paid it in Q4 FY26. No other major regulatory penalties or tax demands are disclosed in FY26. Credit rating agencies (ICRA) rate the company A+ on fund-based facilities, signaling no systemic solvency risk.

Related-party transactions: The company sold ₹75 Cr in goods and services to subsidiaries and associates. Payments to Key Managerial Personnel (directors’ remuneration and sitting fees) totaled ₹34 Cr (standalone). The quantum is reasonable for a ₹2,466 Cr revenue company. No egregious connected-party trading noted.

*Red flags: none.

Cautions (not red, orange): The company’s sugar unit closures involved ₹440 Cr in VRS payouts, a large one-time expense. This signals execution risk on future restructuring (e.g., sodium hypochlorite capex if court appeals succeed). The extended power-cost dispute with Telangana discoms (2022–2026, now paid) hints at regulatory unpredictability in Telangana, a risk for a company with major assets there.

Pledged shares: 1.02% of equity (per Screener), minimal. No promoter shares are under the hammer.

14. Industry Roast & Macro Context

The chlor-alkali business is a pricing war fought with steam and electricity. Global caustic soda supply ballooned in the past decade as China and Asia added capacity. Prices softened from ₹35–40/kg in FY22 to ₹25–30/kg by H2 FY25, squeezing realisations. The industry is also battling environmental regulation: caustic soda’s co-product is chlorine gas, notoriously hazardous to handle and dispose of. Tighter air and water norms in India are slowly raising the cost structure.

Andhra Sugars benefits from having a captive power plant and integrated chlor-alkali capability at Saggonda. The Saggonda complex is a 30+ year old integrated facility with in-house sulphuric acid, chlorine, and caustic production. This is a moat against new entrants but also a liability if margins stay depressed—the capex to upgrade or exit is sunk.

Sulphuric acid is another commodity. Global prices weakened as battery-grade acid demand softened in FY25–26 due to EV slowdown. Andhra Sugars’ new sulphuric acid plant (FY25 commissioning) came online just as margins compressed. The plant is feeding internal consumption (chlor-alkali, specialty chemical production), but some offtake is to external markets. Expect low single-digit margins (2–4%) until market conditions improve.

The ISRO propellant business is different. Liquid rocket propellants (LPSC supplies to ISRO) are specialty chemicals with higher margins and longer contracts. Offtake grew 95% YoY (₹35→₹68 Cr) in FY26. If India’s space programme holds budget allocation (no guarantee), this becomes a multi-hundred-crore opportunity. The Chinese market for propellants is also an upside (if geopolitics permit), but no exports to China are disclosed.

Macro backdrop: Indian chemical exports are facing headwinds from Chinese dumping (especially commodity caustic soda, now at ₹20/kg in international markets). FY26 saw some recovery in global chemical prices, but the reprieve is fragile. If global recession hits, caustic prices will plumb depths again. Andhra Sugars has almost zero hedging; it’s a price-taker.

Sectors to roast: Sugar subsidies and government-backed mills continue to distort the market. Cooperative and private mills in southern India are propped up by government cane-purchase guarantees and subsidy schemes, making competition chaotic. Andhra Sugars exited wisely; the others are stuck.

15. EduInvesting Verdict

A balance sheet with nothing to hide and a chemical business with something to prove: that’s the central tension.

Andhra Sugars is not broken, just unresolved. The sugar mills are closed, the balance sheet is pristine, and ISRO offtake is climbing. None of this is growth; all of it is stabilization. For an investor seeking a re-rating, the question is whether ₹6–7 in normalized annual EPS can compound to ₹10–12 over 3–5 years, and whether that re-rating justifies holding at 11x P/E today. The margin recovery in Q1 FY26 (caustic PBIT margin 16.9%) is a data point, not a trend. The real test is Q2–Q4 FY26. If caustic realisations hold above ₹30/kg and ISRO offtake accelerates further, the platform is set. If realisations slip back to ₹25/kg and ISRO demand stalls, the company reverts to a 6–8% ROE business forever.

The market is pricing in the slow option. History will judge whether the company chooses the bold one.